Yesterday the NHS Accelerated Access Collaborative, in partnership with the AHSN Network, announced which NHS organisations have been successful in their application to the Pathway Transformation Fund (PTF).
Following a very competitive process, almost £2.8m has been made available to 51 projects in integrated care systems, clinical commissioning groups and trusts across England to help them integrate supported rapid uptake products into everyday practice.
In our region, this includes five organisations using FeNO testing to help clinicians more accurately diagnose asthma increase through the use of fractional exhaled nitric oxide (FeNO) testing:
Nick Clarke, Principal Advisor at Eastern AHSN, said:
“I’m really happy that we had some successful applications from our region. On behalf of the AAC and the AHSN network I would like to thank everyone who applied. We received an unprecedented volume and value of projects and were delighted with the level of interest we received but sadly we haven’t been able to fund all of the projects.
“Even if your organisation was unsuccessful in accessing pathway transformation funding, we would still like to offer non-financial support to organisations interested in implementing rapid uptake products.”
• A fractional exhaled nitric oxide (FeNO) test measures the level of nitric oxide in the exhaled breath and can help differentiate between allergic (eosinophilic) and non-allergic asthma.
• The test is non-invasive, easy to perform, and results are often available within seconds. It should be used alongside a patient’s own clinical history and other tests to support a diagnosis of asthma.
• Measuring FeNO concentration in the patient’s breath helps support a more accurate diagnosis and ensures patients are prescribed the correct medication in the appropriate dosage. It can also be used to monitor a patient’s treatment.
The next phase of the Pathway Transformation Fund is focused on supporting the rollout of Tamoxifen, a preventative treatment for people with a history of breast cancer. Applications for funding for this product will be accepted from 7 June to 9 July. Contact [email protected] for support in your application.
The Rapid Uptake Products (RUP) programme supports stronger adoption and spread of NICE approved proven innovations targeting clinical priorities as set out in the NHS Long Term Plan.
The 2021/22 supported RUPs are: Lipid Management; a NICE-approved clinical pathway to help reduce cholesterol, Asthma Biologics, a treatment for severe Asthma , FeNO Testing, which aids diagnosis of Asthma and Tamoxifen as a preventative treatment for breast cancer. Funding has to date been made available for the first three RUPs and organisations will have the opportunity to apply for funding for Tamoxifen projects from June onwards.
For the latest update visit the Accelerated Access Collaborative website.
Do you have a great idea that could make a positive health impact?Get involved